Table 1. Malignancies in the Validation Cohort by TP53 Variant.
Table displaying the breakdown of genotyping for the two p53 variants (G215C, A639G). Thirty-nine total were available for analysis. The numbers of samples for each primary cancer diagnosis harboring G215C, A639G or neither are shown. “Sequencing failed” indicates samples for which we were unable to establish a genotype due to failure of sequencing reaction. Of note, no sample harbored both variants. Frequencies for all cancer types except HD were too small to analyze. The frequencies of each variant in HD were compared to the total of all other types combined. Proportions of HD with p53 variants did not differ from other types (p-value approximately 0.9). HD – Hodgkin Disease, AML – Acute myeloid Leukemia, ALL – Acute lymphoid leukemia, NHL – Non-Hodgkin Lymphoma
| Primary Cancer | No G215C Variant |
G215C present |
Sequencing failed |
No A639G Variant |
A639G present |
Sequencing failed |
|---|---|---|---|---|---|---|
| HD | 20 | 2 | 2 | 19 | 2 | 3 |
| Osteosarcoma | 3 | 0 | 0 | 3 | 0 | 0 |
| Wilms’ Tumor | 1 | 0 | 0 | 0 | 1 | 0 |
| Soft tissue sarcoma |
0 | 0 | 1 | 1 | 0 | 0 |
| Neuroblastoma | 1 | 0 | 0 | 1 | 0 | 0 |
| Astrocytoma | 1 | 0 | 0 | 1 | 0 | 0 |
| Ewing’s Sarcoma | 2 | 0 | 1 | 2 | 1 | 0 |
| AML | 1 | 2 | 0 | 2 | 0 | 1 |
| ALL | 0 | 0 | 1 | 1 | 0 | 0 |
| NHL | 0 | 1 | 0 | 1 | 0 | 0 |
| Total | 39 | 39 | ||||